Oral Coenzyme Q10 Supplementation in Patients with Nonalcoholic Fatty Liver Disease: Effects on Serum Vaspin, Chemerin, Pentraxin 3, Insulin Resistance and Oxidative Stress-Reference-Cited by-同舟云学术

Oral Coenzyme Q10 Supplementation in Patients with Nonalcoholic Fatty Liver Disease: Effects on Serum Vaspin, Chemerin, Pentraxin 3, Insulin Resistance and Oxidative Stress

Published:2014-10 Issue:7 Volume:45 Page:589-595
ISSN:0188-4409
Container-title:Archives of Medical Research
language:en
Short-container-title:Archives of Medical Research

Author:

Farhangi Mahdieh Abbasalizad,Alipour Beytollah,Jafarvand Elnaz,Khoshbaten Manouchehr

Publisher

Elsevier BV

Subject

General Medicine

Reference45 articles.

1. Nonalcoholic fatty liver disease;Erickson;J Lipid Res,2009

2. Chemerin in non-alcoholic fatty liver disease? Up or down?;Buechler;Endocrinol Metab Syndr,2013

3. Nonalcoholic fatty liver disease: from steatosis to cirrhosis;Farrell;Hepatology,2006

4. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity;Browning;Hepatology,2004

5. The natural history of non-alcoholic fatty liver disease: a population-based cohort study;Adams;Gastroenterology,2005

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. S2k-Leitlinie Klinische Ernährung in der Hepatologie;Aktuelle Ernährungsmedizin;2024-08

2. The effect of coenzyme Q10 intake on metabolic profiles in women candidates for in-vitro fertilization: a randomised trial;Annals of Medicine & Surgery;2024-04-26

3. Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial;Trials;2024-03-02

4. Effects of coenzyme Q10 supplementation on oxidative stress biomarkers following reperfusion in STEMI patients undergoing primary percutaneous coronary intervention;Journal of Cardiovascular and Thoracic Research;2023-12-30

5. Prevention of contrast induced-acute kidney injury using coenzyme Q10 in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention;European Journal of Clinical Pharmacology;2023-08-01